CLEVELAND, Jan. 18, 2017 – Athersys, Inc. (NASDAQ:ATHX) announced today that through its Belgian subsidiary, ReGenesys BVBA (ReGenesys), it has entered into an agreement with a global leader in the animal health business segment to evaluate the cell therapy technology for application in a non-disclosed animal health area. Under the terms of the agreement, ReGenesys will receive an initial payment in exchange for an exclusive period to evaluate the cell therapy technology with an option to negotiate for a license for the development and commercialization of the technology for this area. Additional details were not disclosed.
J.P. Morgan 35th Annual Healthcare Conference 2017
J.P. Morgan 35th Annual Healthcare Conference 2017
January 9-12, 2017
San Francisco, CA
2016 BIO EUROPE INTERNATIONAL PARTNERING CONFERENCE
2016 BIO EUROPE INTERNATIONAL PARTNERING CONFERENCE
Destum Partners Attends the 2015 BIO Europe International Partnering Conference
November 7–9, 2016
Cologne, Germany